Sign in →

Test Code MISCLM Porphobilinogen Deaminase, Whole Blood

Important Note

 

 

Additional Codes

 

MAYO Test ID

PBGD

EPIC Test ID

LAB2608

 

Reporting Name

PBG Deaminase, WB

Useful For

Confirmation of a diagnosis of acute intermittent porphyria

Method Name

Enzymatic End Point/Spectrofluorometric

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Whole blood


Ordering Guidance


This test is for diagnosis of acute intermittent porphyria. Porphobilinogen deaminase, also known as uroporphyrinogen I synthase, is commonly confused with uroporphyrinogen III synthase, the enzyme deficient in congenital erythropoietic porphyria (CEP). For CEP cases, order UPGC / Uroporphyrinogen III Synthase (Co-Synthase), Erythrocytes.



Necessary Information


1. Patient’s age is required

2. Include a list of medications the patient is currently taking.



Specimen Required


Patient Preparation: Patient must not consume any alcohol for 24 hours before specimen collection. This is essential as ethanol induces porphobilinogen deaminase activity, which may lead to a false-normal result.

Container/Tube:

Preferred: Green top (sodium heparin)

Acceptable: Lavender top (EDTA) or green top (lithium heparin)

Specimen Volume: 4 mL

Collection Instructions: Refrigerate specimen as soon as possible.


Specimen Minimum Volume

3 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Whole blood Refrigerated (preferred) 8 days
  Ambient  7 days

Reject Due To

Gross hemolysis Reject

Reference Values

Reference ranges have not been established for patients who are younger than 16 years.

 

≥7.0 nmol/L/sec

6.0-6.9 nmol/L/sec (indeterminate)

<6.0 nmol/L/sec (diminished)

Day(s) Performed

Tuesday

CPT Code Information

82657

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PBGD_ PBG Deaminase, WB 12810-8

 

Result ID Test Result Name Result LOINC Value
4022 PBG Deaminase, WB 12810-8
28400 Interpretation 59462-2
606470 Reviewed By 18771-6

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

Report Available

2 to 8 days

Forms

1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing-Spanish (T826)

2. If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.